Related Experiment Video

Updated: Jun 4, 2026

Ex Vivo Culture of Circulating Tumor Cells in the Cerebral Spinal Fluid from Melanoma Patients to Study Melanoma-Associated Leptomeningeal Disease
06:25

Ex Vivo Culture of Circulating Tumor Cells in the Cerebral Spinal Fluid from Melanoma Patients to Study Melanoma-Associated Leptomeningeal Disease

Published on: March 29, 2024

Targeting the insulin-like growth factor network in cancer therapy

Isabel Heidegger1, Andreas Pircher, Helmut Klocker

  • 1Department of Urology, Division of Experimental Urology, Innsbruck Medical University, Innsbruck, Austria.

Cancer Biology & Therapy
|February 12, 2011
PubMed

Insights

Changes in insulin-like growth factor (IGF) signaling are linked to cancer development. This review examines IGF1 receptor (IGF1R) as a cancer target, discussing drugs and clinical trials.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Alterations in insulin-like growth factor (IGF) signaling pathways are implicated in cancer pathogenesis.
  • The IGF axis represents a significant target for novel cancer therapies.
  • Numerous therapeutic agents targeting the IGF axis have been developed.

Purpose of the Study:

  • To provide a comprehensive overview of the IGF axis, its signaling mechanisms, and its role in neoplasia.
  • To critically evaluate preclinical and clinical studies focusing on the IGF1 receptor (IGF1R) as a cancer therapeutic target.
  • To discuss the preliminary outcomes and potential challenges associated with IGF1R-targeted cancer therapies.

Main Methods:

  • Literature review of preclinical and clinical studies on IGF axis and IGF1R in oncology.
  • Analysis of various drug modalities targeting the IGF axis, including monoclonal antibodies, tyrosine kinase inhibitors, antisense oligonucleotides, and IGF-binding proteins.
  • Synthesis of current data on IGF1R's role in cancer and ongoing clinical trials.

Main Results:

  • The IGF axis is a critical regulator in cancer development and progression.
  • Over 60 clinical trials are investigating IGF1R as a therapeutic target, highlighting its significance in oncology.
  • Various drug classes show promise but face challenges that require further investigation.

Conclusions:

  • The IGF axis, particularly IGF1R, is a validated and actively pursued target in cancer therapy.
  • Continued research and clinical evaluation are essential to overcome limitations and optimize IGF1R-targeted treatments.
  • Understanding the complexities of IGF signaling is crucial for advancing oncology drug development.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...